arrow
M

Monzr M. Al Malki

city of hope national medical center
H指数:39
被引数:5,317

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hematopoietic Cell Transplantation Outcomes in the Era of Post-Transplant Cyclophosphamide: Comprehensive Donor Analysis

移植后环磷酰胺时代的造血细胞移植结局:全面的供者分析

2026-10-230
OA
Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort

HLA错配无关供者减低强度移植后移植抗宿主病预防的术后环磷酰胺方案II期研究:ACCESS试验扩展队列结果

2026-09-010
OAAI
Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS Trial

不匹配无关供者造血细胞移植中的感染负担:ACCESS试验的结果

2026-07-160
OA
CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide

CHIME:一种新型HLA表位模型与含移植后环磷酰胺的半相合造血细胞移植的非复发死亡率相关

2026-07-040
OA
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

异基因造血干细胞移植(allo-HCT)在采用氟达拉滨/美法仑(Fludarabine/Melphalan)预处理和他克莫司/西罗莫司(Tacrolimus/Sirolimus)移植物抗宿主病(GVHD)预防方案的急性髓系白血病(AML)中的长期生存结局。

2025-11-180
OAAI
Matched Unrelated vs Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

匹配无关供者与半合子相合供者造血细胞移植使用移植后环磷酰胺

2025-10-080
OAAI
Performance of treatment response assessment at day 7 by baseline acute graft-vs-host disease severity

基于基线急性移植物抗宿主病严重程度的第7天治疗反应评估表现

2025-09-250
PRE
Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis

异基因造血细胞移植治疗骨髓纤维化受者中中性粒细胞植入期间的肺部表现

2025-09-240
OA
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML

在IDH-2突变急性髓系白血病异基因造血细胞移植后使用enasidenib维持治疗的试验

2025-09-190
PRE
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia

靶向治疗和免疫疗法在TP53突变急性淋巴细胞白血病患者中的疗效

2025-09-010
PRE
Outcomes After Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment

基于美法仑的减低强度异基因造血细胞移植在肾功能不全患者中的结局

2025-07-010
PRE
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR

异基因造血细胞供者选择:NMDP/CIBMTR当代指南

2025-07-010
PREAI
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703

基于移植后环磷酰胺的GVHD预防在70岁及以上患者中的影响:BMT CTN 1703的更新

2025-05-050
OA
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant CyclophosphamideBased Graft-Versus-Host Disease Prophylaxis

供体类型不影响低强度异基因造血细胞移植后的晚期移植失败,移植后基于环磷酰胺的移植物抗宿主病预防

2025-03-010
PRE
Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect

基于美法仑的预处理联合移植后环磷酰胺用于外周血干细胞移植:供者效应

2025-02-270
OA
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis
2025-02-200
OAAI
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
2024-10-011
PRE